<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The severity of <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> in diabetic patients varies for unclear reasons </plain></SENT>
<SENT sid="1" pm="."><plain>Long-term use of <z:chebi fb="0" ids="6801">metformin</z:chebi> is associated with <z:hpo ids='HP_0002024'>malabsorption</z:hpo> of vitamin B(12) (<z:chebi fb="1" ids="30411">cobalamin</z:chebi> [<z:chebi fb="0" ids="28911">Cbl</z:chebi>]) and elevated <z:chebi fb="0" ids="17230">homocysteine</z:chebi> (<z:chebi fb="0" ids="17230">Hcy</z:chebi>) and <z:chebi fb="0" ids="30860">methylmalonic acid</z:chebi> (<z:chebi fb="0" ids="34840">MMA</z:chebi>) levels, which may have deleterious effects on peripheral nerves </plain></SENT>
<SENT sid="2" pm="."><plain>The intent of this study was to clarify the relationship among <z:chebi fb="0" ids="6801">metformin</z:chebi> exposure, levels of <z:chebi fb="0" ids="28911">Cbl</z:chebi>, <z:chebi fb="0" ids="17230">Hcy</z:chebi>, and <z:chebi fb="0" ids="34840">MMA</z:chebi>, and severity of <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> in diabetic patients </plain></SENT>
<SENT sid="3" pm="."><plain>We hypothesized that <z:chebi fb="0" ids="6801">metformin</z:chebi> exposure would be associated with lower <z:chebi fb="0" ids="28911">Cbl</z:chebi> levels, elevated <z:chebi fb="0" ids="17230">Hcy</z:chebi> and <z:chebi fb="0" ids="34840">MMA</z:chebi> levels, and more severe <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: This was a prospective case-control study of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and concurrent symptomatic <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo>, comparing those who had received &gt;6 months of <z:chebi fb="0" ids="6801">metformin</z:chebi> therapy (n = 59) with those without <z:chebi fb="0" ids="6801">metformin</z:chebi> exposure (n = 63) </plain></SENT>
<SENT sid="5" pm="."><plain>Comparisons were made using clinical (Toronto Clinical Scoring System and <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e> Impairment Score), laboratory (serum <z:chebi fb="0" ids="28911">Cbl</z:chebi>, fasting <z:chebi fb="0" ids="17230">Hcy</z:chebi>, and fasting <z:chebi fb="0" ids="34840">MMA</z:chebi>), and electrophysiological measures (nerve conduction studies) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="6801">Metformin</z:chebi>-treated patients had depressed <z:chebi fb="0" ids="28911">Cbl</z:chebi> levels and elevated fasting <z:chebi fb="0" ids="34840">MMA</z:chebi> and <z:chebi fb="0" ids="17230">Hcy</z:chebi> levels </plain></SENT>
<SENT sid="7" pm="."><plain>Clinical and electrophysiological measures identified more severe <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> in these patients; the cumulative <z:chebi fb="0" ids="6801">metformin</z:chebi> dose correlated strongly with these clinical and paraclinical group differences </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> exposure may be an iatrogenic cause for exacerbation of <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Interval screening for <z:chebi fb="0" ids="28911">Cbl</z:chebi> deficiency and systemic <z:chebi fb="0" ids="28911">Cbl</z:chebi> therapy should be considered upon initiation of, as well as during, <z:chebi fb="0" ids="6801">metformin</z:chebi> therapy to detect potential secondary causes of worsening <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> </plain></SENT>
</text></document>